This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Meta-Analysis

. 2014 Dec 15;347(1-2):408-10.

doi: 10.1016/j.jns.2014.10.029. Epub 2014 Oct 22.

Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together

Andrea Messori¹, Valeria Fadda², Dario Maratea², Sabrina Trippoli²

Affiliations

Affiliations

¹ HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy. Electronic address: andrea.messori.it@gmail.com.
² HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy.

PMID: 25455308
DOI: 10.1016/j.jns.2014.10.029

Meta-Analysis

Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together

Andrea Messori et al. J Neurol Sci. 2014.

. 2014 Dec 15;347(1-2):408-10.

doi: 10.1016/j.jns.2014.10.029. Epub 2014 Oct 22.

Authors

Andrea Messori¹, Valeria Fadda², Dario Maratea², Sabrina Trippoli²

Affiliations

¹ HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy. Electronic address: andrea.messori.it@gmail.com.
² HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy.

PMID: 25455308
DOI: 10.1016/j.jns.2014.10.029

No abstract available

Keywords: Azathioprine; Beta interferons; Meta-analysis; Multiple sclerosis.

PubMed Disclaimer

Similar articles

Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, La Mantia L, Repice A, Solari A, Tedeschi G, Milanese C. Massacesi L, et al. PLoS One. 2014 Nov 17;9(11):e113371. doi: 10.1371/journal.pone.0113371. eCollection 2014. PLoS One. 2014. PMID: 25402490 Free PMC article. Clinical Trial.
Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
Pulicken M, Bash CN, Costello K, Said A, Cuffari C, Wilterdink JL, Rogg JM, Mills P, Calabresi PA. Pulicken M, et al. Mult Scler. 2005 Apr;11(2):169-74. doi: 10.1191/1352458505ms1141oa. Mult Scler. 2005. PMID: 15794390 Clinical Trial.
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E. Kalincik T, et al. Clin Neurol Neurosurg. 2012 Sep;114(7):940-6. doi: 10.1016/j.clineuro.2012.02.014. Epub 2012 Mar 7. Clin Neurol Neurosurg. 2012. PMID: 22402204 Clinical Trial.
Current disease-modifying therapies in multiple sclerosis.
Kieseier BC, Hartung HP. Kieseier BC, et al. Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138. Semin Neurol. 2003. PMID: 12894379 Review.
[Emerging new therapies for relapsing remitting multiple sclerosis].
Anis S, Achiron A. Anis S, et al. Harefuah. 2014 Nov;153(11):658-62, 687, 686. Harefuah. 2014. PMID: 25563027 Review. Hebrew.

See all similar articles

Cited by

Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis.
Badiani B, Maratea D, Messori A. Badiani B, et al. World J Clin Oncol. 2015 Aug 10;6(4):73-9. doi: 10.5306/wjco.v6.i4.73. World J Clin Oncol. 2015. PMID: 26266104 Free PMC article.
Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.
Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Brummer T, et al. Ther Adv Neurol Disord. 2021 Aug 23;14:17562864211035542. doi: 10.1177/17562864211035542. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34457039 Free PMC article. Review.
[Effectiveness and tolerance of azathioprine as first-line treatment for multiple sclerosis: a case study from Morocco].
Mirhani A, Auajjar N, Slimani C, Attarassi B. Mirhani A, et al. Pan Afr Med J. 2024 Sep 18;49:16. doi: 10.11604/pamj.2024.49.16.38051. eCollection 2024. Pan Afr Med J. 2024. PMID: 39711832 Free PMC article. French.
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
Aly L, Hemmer B, Korn T. Aly L, et al. Curr Neuropharmacol. 2017;15(6):874-891. doi: 10.2174/1570159X14666161208151525. Curr Neuropharmacol. 2017. PMID: 27928949 Free PMC article. Review.
A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis-A Prospective Cohort Study.
Agrawal A, Srivastava MVP, Bhatia R, Goyal V, Singh MB, Vishnu VY, Prabhakar A. Agrawal A, et al. Brain Sci. 2023 Aug 27;13(9):1249. doi: 10.3390/brainsci13091249. Brain Sci. 2023. PMID: 37759850 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information